Tekla Capital Management LLC acquired a new position in Altimmune, Inc. (NASDAQ:ALT – Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,000 shares of the company’s stock, valued at approximately $316,000. Tekla Capital Management LLC owned approximately […]
Altimmune (NASDAQ:ALT – Get Free Report) and Purple Biotech (NASDAQ:PPBT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership. Profitability This table compares Altimmune and Purple Biotech’s […]
Altimmune (NASDAQ:ALT – Get Free Report) and Incannex Healthcare (NASDAQ:IXHL – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk. Profitability This table compares Altimmune and Incannex Healthcare’s […]
Altimmune (NASDAQ:ALT – Get Free Report) and Neoleukin Therapeutics (NASDAQ:NLTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation. Analyst Ratings This is a breakdown of current […]
Shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 1-year price […]